BerGenBio has announced the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021.
Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the company with immediate effect to pursue other business interests.
“I have thoroughly enjoyed my past twelve years at BerGenBio and will keenly watch the progress with bemcentinib as it progresses through the exciting next steps. Now is a natural time for me to hand over to Martin. I wish the Board and whole team every success for the future,” says Richard Godfrey.
Rune Skeie, Chief Financial Officer of BerGenBio, assumed the role of interim CEO until 8 September 2021.
Martin Olin brings more than 20 years of executive experience in the pharmaceutical and biotechnology industry to BerGenBio. He previously served as CEO of Symphogen, a biotechnology company focused on the development of protein drugs based on recombinant monoclonal antibody mixtures, acquired by Servier in 2020.
Before joining Symphogen in 2012, Olin was a senior partner with SLS Invest, a Scandinavian based healthcare focused private equity fund. Previously, he held managerial positions in Novo Nordisk including Finance Director, EMEA. Most recently he has served as Managing Partner of Nordic Eye, a Copenhagen based Venture Capital firm.
“BerGenBio has pioneered the understanding of AXL biology and the potential of AXL inhibition as a cornerstone therapy for the treatment of serious diseases. I am very excited to join the Company and look forward to working with the board and team to continue the progression of our lead candidate bemcentinib, as well as the pipeline of drug candidates, through further clinical development and ultimately to the patients we believe will benefit from them,” says Martin Olin, Chief Executive Officer of BerGenBio.
Photo of Martin Olin